Teva Pharma Industries Stock Probability of Future Stock Price Finishing Over 16.5

TEVA Stock  USD 16.50  0.31  1.84%   
Teva Pharma's future price is the expected price of Teva Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Teva Pharma Industries performance during a given time horizon utilizing its historical volatility. Check out Teva Pharma Backtesting, Teva Pharma Valuation, Teva Pharma Correlation, Teva Pharma Hype Analysis, Teva Pharma Volatility, Teva Pharma History as well as Teva Pharma Performance.
  
The current year's Price Earnings To Growth Ratio is expected to grow to 0.34, whereas Price To Sales Ratio is forecasted to decline to 0.70. Please specify Teva Pharma's target price for which you would like Teva Pharma odds to be computed.

Teva Pharma Target Price Odds to finish over 16.5

The tendency of Teva Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 16.50 90 days 16.50 
roughly 96.0
Based on a normal probability distribution, the odds of Teva Pharma to move above the current price in 90 days from now is roughly 96.0 (This Teva Pharma Industries probability density function shows the probability of Teva Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Teva Pharma Industries has a beta of -0.53. This usually implies as returns on the benchmark increase, returns on holding Teva Pharma are expected to decrease at a much lower rate. During a bear market, however, Teva Pharma Industries is likely to outperform the market. Additionally Teva Pharma Industries has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Teva Pharma Price Density   
       Price  

Predictive Modules for Teva Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Teva Pharma Industries. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Teva Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
14.7016.5618.42
Details
Intrinsic
Valuation
LowRealHigh
10.5912.4518.15
Details
12 Analysts
Consensus
LowTargetHigh
9.6110.5611.72
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.610.620.62
Details

Teva Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Teva Pharma is not an exception. The market had few large corrections towards the Teva Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Teva Pharma Industries, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Teva Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.08
β
Beta against Dow Jones-0.53
σ
Overall volatility
0.60
Ir
Information ratio -0.11

Teva Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Teva Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Teva Pharma Industries can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Teva Pharma generated a negative expected return over the last 90 days
Teva Pharma Industries currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B.
Teva Pharma has a strong financial position based on the latest SEC filings
About 58.0% of Teva Pharma shares are owned by institutional investors
Latest headline from finance.yahoo.com: Tamiflu Market Set to Surpass 2.7 Billion by 2034, Driven by Rising Influenza Cases and Key Developments

Teva Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Teva Stock often depends not only on the future outlook of the current and potential Teva Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Teva Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.1 B
Cash And Short Term Investments3.2 B

Teva Pharma Technical Analysis

Teva Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Teva Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Teva Pharma Industries. In general, you should focus on analyzing Teva Stock price patterns and their correlations with different microeconomic environments and drivers.

Teva Pharma Predictive Forecast Models

Teva Pharma's time-series forecasting models is one of many Teva Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Teva Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Teva Pharma Industries

Checking the ongoing alerts about Teva Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Teva Pharma Industries help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Teva Pharma generated a negative expected return over the last 90 days
Teva Pharma Industries currently holds 20.15 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 15.85 B. Net Loss for the year was (615 M) with profit before overhead, payroll, taxes, and interest of 6.97 B.
Teva Pharma has a strong financial position based on the latest SEC filings
About 58.0% of Teva Pharma shares are owned by institutional investors
Latest headline from finance.yahoo.com: Tamiflu Market Set to Surpass 2.7 Billion by 2034, Driven by Rising Influenza Cases and Key Developments
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.85)
Revenue Per Share
14.879
Quarterly Revenue Growth
0.125
Return On Assets
0.0556
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.